Engineering 5-flourouracil and Leucovorin-loaded Vesicular Systems for Possible Colon Specific Delivery: Evaluation and Real Time Cell Assay Against HCT-116 Colon Cell Lines

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Apr 24

PMID 38655322

Authors

Onyinyechi Lydia Ugorji

Ikechukwu Virgilius Onyishi

Amarauche Chukwu

Anthony Amaechi Attama

Affiliations

Soon will be listed here.

Abstract

5-flourouracil (5-FU) is typically modulated with leucovorin (LEU) in clinical practice to improve clinical efficacy and patient survival rates. However, this combination has undesirable side effects and makes 5-FU more toxic. Hence, integrating a vesicular system (proniosomes) with another delivery vehicle may improve drug targeting, while resolving the aforementioned drawbacks. This study aimed to engineer 5-FU/LEU proniosomes for possible delivery to the colon. The modified slurry approach was used to create drug-loaded proniosomes (150 mg/9 g of carrier) using both water-soluble (dextrin (DEX) and lactose (LAC)) and insoluble (Neusilin FH (NEU)) carriers. The powdered formulations were filled into Eudragit S100 (10 %)-coated capsules or Eudragit FS 30D capsules for enteric- or colon-specific delivery. In vitro evaluations (flow properties, powder X-ray diffractometry (XRD) analysis, particle size analysis, entrapment efficiency, drug release, scanning electron microscopy (SEM), polydispersity index, Fourier transform infrared spectroscopy (FTIR), and stability studies) were performed on the formulations. An cytotoxicity test [real-time cell assay (RTCA)] against HCT-116 colon cancer cell lines was performed using the optimized formulation. evaluations showed that the nanoparticles had good physicochemical properties. RTCA studies showed sustained cell death with the formulations compared to the pure drug and placebo. The sequential drug release of the colon-targeted capsules containing 5-FU and LEU- loaded proniosomes showed negligible drug release in SGF (pH 1.2) and phosphate buffer solution (pH 6.8) (approximately 11 %) but profound drug release (>80 %) at pH 7.4. Drug-loaded proniosomes engineered for colon targeting (Eudragit S100 (10 %) capsules or Eudragit FS 30D capsules) showed good colon-specific targeting and favorable cytotoxicity profiles.

References

Mousazadeh N, Gharbavi M, Rashidzadeh H, Nosrati H, Danafar H, Johari B . Anticancer evaluation of methotrexate and curcumin-coencapsulated niosomes against colorectal cancer cell lines. Nanomedicine (Lond). 2022; 17(4):201-217. DOI: 10.2217/nnm-2021-0334. View

Gulbake A, Jain A, Jain A, Jain A, Jain S . Insight to drug delivery aspects for colorectal cancer. World J Gastroenterol. 2016; 22(2):582-99. PMC: 4716061. DOI: 10.3748/wjg.v22.i2.582. View

Oktem O, Bildik G, Senbabaoglu F, Lack N, Akin N, Yakar F . Cytotoxicity and mitogenicity assays with real-time and label-free monitoring of human granulosa cells with an impedance-based signal processing technology intergrating micro-electronics and cell biology. Reprod Toxicol. 2016; 60:82-91. DOI: 10.1016/j.reprotox.2015.12.005. View

Firouzi Amandi A, Jokar E, Eslami M, Dadashpour M, Rezaie M, Yazdani Y . Enhanced anti-cancer effect of artemisinin- and curcumin-loaded niosomal nanoparticles against human colon cancer cells. Med Oncol. 2023; 40(6):170. DOI: 10.1007/s12032-023-02032-7. View

Wang C, Luo X, Zhang B, Song W, Ni M, Mehendale S . Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells. Cancer Chemother Pharmacol. 2006; 60(1):69-79. PMC: 2657471. DOI: 10.1007/s00280-006-0350-2. View

Pourgholi A, Dadashpour M, Mousapour A, Firouzi Amandi A, Zarghami N . Anticancer Potential of Silibinin Loaded Polymeric Nanoparticles against Breast Cancer Cells: Insight into the Apoptotic Genes Targets. Asian Pac J Cancer Prev. 2021; 22(8):2587-2596. PMC: 8629447. DOI: 10.31557/APJCP.2021.22.8.2587. View

Naeem M, Choi M, Cao J, Lee Y, Ikram M, Yoon S . Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy. Drug Des Devel Ther. 2015; 9:3789-99. PMC: 4516197. DOI: 10.2147/DDDT.S88672. View

Korsmeyer R, Gurny R, Doelker E, Buri P, Peppas N . Mechanisms of potassium chloride release from compressed, hydrophilic, polymeric matrices: effect of entrapped air. J Pharm Sci. 1983; 72(10):1189-91. DOI: 10.1002/jps.2600721021. View

Mathers C, Loncar D . Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3(11):e442. PMC: 1664601. DOI: 10.1371/journal.pmed.0030442. View

10.

Safari Sharafshadeh M, Tafvizi F, Khodarahmi P, Ehtesham S . Preparation and physicochemical properties of cisplatin and doxorubicin encapsulated by niosome alginate nanocarrier for cancer therapy. Int J Biol Macromol. 2023; 235:123686. DOI: 10.1016/j.ijbiomac.2023.123686. View

11.

Katsidzira L, Gangaidzo I, Thomson S, Rusakaniko S, Matenga J, Ramesar R . The shifting epidemiology of colorectal cancer in sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2017; 2(5):377-383. DOI: 10.1016/S2468-1253(16)30183-2. View

12.

Peppas N . 1. Commentary on an exponential model for the analysis of drug delivery: Original research article: a simple equation for description of solute release: I II. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres,.... J Control Release. 2014; 190:31-2. View

13.

Nasr A, Elhady S, Swidan S, Badawi N . Celecoxib Loaded In-Situ Provesicular Powder and Its In-Vitro Cytotoxic Effect for Cancer Therapy: Fabrication, Characterization, Optimization and Pharmacokinetic Evaluation. Pharmaceutics. 2020; 12(12). PMC: 7760804. DOI: 10.3390/pharmaceutics12121157. View

14.

Hosseinpourpia R, Echart A, Adamopoulos S, Gabilondo N, Eceiza A . Modification of Pea Starch and Dextrin Polymers with Isocyanate Functional Groups. Polymers (Basel). 2019; 10(9). PMC: 6403980. DOI: 10.3390/polym10090939. View

15.

Mittal S, Chaudhary A, Chaudhary A, Kumar A . Proniosomes: the effective and efficient drug-carrier system. Ther Deliv. 2020; 11(2):125-137. DOI: 10.4155/tde-2019-0065. View

16.

Mohamed H, El-Shanawany S, Hamad M, Elsabahy M . Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities. Sci Rep. 2017; 7(1):6340. PMC: 5524940. DOI: 10.1038/s41598-017-06955-w. View

17.

Udofot O, Affram K, Israel B, Agyare E . Cytotoxicity of 5-fluorouracil-loaded pH-sensitive liposomal nanoparticles in colorectal cancer cell lines. Integr Cancer Sci Ther. 2015; 2(5):245-252. PMC: 4681526. DOI: 10.15761/icst.1000150. View

18.

Rhodes D . SEM imaging predicts quality of niosomes from maltodextrin-based proniosomes. Pharm Res. 2001; 18(5):656-61. DOI: 10.1023/a:1011037527889. View

19.

Moghassemi S, Hadjizadeh A . Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release. 2014; 185:22-36. DOI: 10.1016/j.jconrel.2014.04.015. View

20.

Manchun S, Dass C, Cheewatanakornkool K, Sriamornsak P . Enhanced anti-tumor effect of pH-responsive dextrin nanogels delivering doxorubicin on colorectal cancer. Carbohydr Polym. 2015; 126:222-30. DOI: 10.1016/j.carbpol.2015.03.018. View